Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats

References

• WHOConsolidation Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV InfectionGeneva, SwitzerlandWorld Health Organization2013
   Google Scholar
• KitchenVSSkinnerCAriyoshiKSafety and activity of saquinavir in HIV infectionLancet199534589559529557715294
   PubMed Web of Science ®Google Scholar
• NobleSFauldsDSaquinavir. A review of its pharmacology and clinical potential in the management of HIV infectionDrugs1996521931128799687
   PubMed Web of Science ®Google Scholar
• FitzsimmonsMECollinsJMSelective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4 potential contribution to high first-pass metabolismDrug Metab Dispos19972522562669029057
   PubMed Web of Science ®Google Scholar
• KimAEDintamanJMWaddellDSSilvermanJASaquinavir, an HIV protease inhibitor, is transported by P-glycoproteinJ Pharmacol Exp Ther19982863143914459732409
   PubMed Web of Science ®Google Scholar
• GiovinazzoGIngrossoIParadisoADe GaraLSantinoAResveratrol biosynthesis: plant metabolic engineering for nutritional improvement of foodPlant Foods Hum Nutr201267319119922777386
   PubMed Web of Science ®Google Scholar
• SunAYSimonyiASunGYThe “French Paradox” and beyond: neuroprotective effects of polyphenolsFree Radic Biol Med200232431431811841921
   PubMed Web of Science ®Google Scholar
• CriquiMHRingelBLDoes diet or alcohol explain the French paradox?Lancet19943448939171917237996999
   PubMed Web of Science ®Google Scholar
• FrémontLBiological effects of resveratrolLife Sci200066866367310680575
   PubMed Web of Science ®Google Scholar
• FanEZhangLJiangSBaiYBeneficial effects of resveratrol on atherosclerosisJ Med Food200811461061419053850
   PubMed Web of Science ®Google Scholar
• JangMCaiLUdeaniGOCancer chemopreventive activity of resveratrol, a natural product derived from grapesScience199727552972182208985016
   PubMed Web of Science ®Google Scholar
• ZhangH-SZhouYWuM-RZhouH-SXuFResveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD(+)-dependent SIRT1 activityLife Sci20098513–1448448919664641
   PubMed Web of Science ®Google Scholar
• ClouserCLChauhanJBessMAAnti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabineBioorg Med Chem Lett201222216642664623010273
   PubMed Web of Science ®Google Scholar
• ChiY-CLinS-PHouY-CA new herb–drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in ratsToxicol Appl Pharmacol2012263331532222813711
   PubMed Web of Science ®Google Scholar
• YangS-YTsaiS-YHouY-CChaoP-DLInductive modulation on P-glycoprotein and cytochrome 3A by resveratrol, a constituent of grapesFood Chem20121333683688
   Web of Science ®Google Scholar
• ZhuangXShenGYuanMLiHInvestigation of the pharmacokinetic interaction between ritonavir and CMDCK, a new non-nucleoside reverse transcriptase inhibitorDrug Res (Stuttg)201363523724223539429
   PubMedGoogle Scholar
• ChoiYHLeeILeeMGEffects of cysteine on metformin pharmacokinetics in rats with protein–calorie malnutrition: partial restoration of some parameters to control levelsJ Pharm Pharmacol200860215316118237462
   PubMed Web of Science ®Google Scholar
• VellonenKSHonkakoskiPUrttiASubstrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicityEur J Pharm Sci200423218118815451006
   PubMed Web of Science ®Google Scholar
• KimS-AKimS-WChoiH-KHanH-KEnhanced systemic exposure of saquinavir via the concomitant use of curcumin-loaded solid dispersion in ratsEur J Pharm Sci201349580080423748001
   PubMed Web of Science ®Google Scholar
• VyasTKShahiwalaAAmijiMMImproved oral bioavailability and brain transport of saquinavir upon administration in novel nanoemulsion formulationsInt J Pharm20083471–29310117651927
   PubMed Web of Science ®Google Scholar
• LiangGLiNMaLEffect of quercetin on the transport of ritonavir to the central nervous system in vitro and in vivoActa Pharm20166619710726959546
   PubMed Web of Science ®Google Scholar
• PiverBBerthouFDreanoYLucasDDifferential inhibition of human cytochrome P450 enzymes by ε-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beveragesLife Sci20037391199121312818727
   PubMed Web of Science ®Google Scholar
• PiverBBerthouFDreanoYLucasDInhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine componentsToxicol Lett20011251839111701226
   PubMed Web of Science ®Google Scholar
• TaubMEPodilaLElyDAlmeidaIFunctional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activityDrug Metab Dispos200533111679168716093365
   PubMed Web of Science ®Google Scholar
• TroutmanMDThakkerDRNovel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epitheliumPharm Res20032081210122412948019
   PubMed Web of Science ®Google Scholar
• SoldnerABenetLZMutschlerEChristiansUActive transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayersBr J pharmacol200012961235124310725273
   PubMed Web of Science ®Google Scholar
• LiuYZengSAdvances in the MDCK-MDR1 cell model and its applications to screen drug permeabilityYao Xue Xue Bao2008436559564 Chinese18822955
   PubMedGoogle Scholar
• ChoiJ-SChoiB-CKangKWEffect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrolPharmazie2009641495219216231
   PubMed Web of Science ®Google Scholar
• ChufanEEKapoorKSimHMMultiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1)PLoS One2013812e8246324349290
   PubMed Web of Science ®Google Scholar
• PajevaIKSterzKChristliebMSteggemannKMarighettiFWieseMInteractions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoproteinChemMedChem20138101701171323943604
   PubMed Web of Science ®Google Scholar
• MartinezLArnaudOHeninEUnderstanding polyspecificity within the substrate-binding cavity of the human multidrug resistance P-glycoproteinFEBS J2014281367368224219411
   PubMed Web of Science ®Google Scholar
• ShapiroABLingVPositively cooperative sites for drug transport by P-glycoprotein with distinct drug specificitiesEur J Biochem199725011301379432000
   PubMedGoogle Scholar
• ChufanEESimH-MAmbudkarSVChapter three – molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studiesJohnDSToshihisaIAdvances in Cancer ResearchAcademic Press20157196
   Google Scholar
• JainRDuvvuriSKansaraVMandavaNKMitraAKIntestinal absorption of novel-dipeptide prodrugs of saquinavir in ratsInt J Pharm2007336223324017207946
   PubMedGoogle Scholar
• BuchananCMBuchananNLEdgarKJPharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulationsBiomacromolecules20089130531318072746
   PubMed Web of Science ®Google Scholar
• HirunpanichVMurakosoKSatoHInhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in ratsInt J Pharm20083511–213314318082981
   PubMedGoogle Scholar
• PathakSMMusmadePDengleSKarthikABhatKUdupaNEnhanced oral absorption of saquinavir with methyl-beta-cyclodextrin – preparation and in vitro and in vivo evaluationEur J Pharm Sci201041344045120656025
   PubMed Web of Science ®Google Scholar
• PathakSMKumarARSubramanianGUdupaNDevelopment and validation of a reversed-phase liquid chromatographic method with fluorescence detection for the study of saquinavir pharmacokinetics in rat plasmaAnal Chim Acta2007594224825617586122
   PubMed Web of Science ®Google Scholar
• KupferschmidtHHFattingerKEHaHRFollathFKrähenbühlSGrapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in manBr J Clin Pharmacol19984543553599578182
   PubMed Web of Science ®Google Scholar
• HaHRFollathFBloemhardYKrähenbühlSDetermination of saquinavir in human plasma by high-performance liquid chromatographyJ Chromatogr B Biomed Sci Appl199769424274339252059
   PubMed Web of Science ®Google Scholar
• FröhlichMBurhenneJMartin-FacklamMOral contraception does not alter single dose saquinavir pharmacokinetics in womenBr J Clin Pharmacol200457324425214998420
   PubMed Web of Science ®Google Scholar
• DaviesNMTakemotoJKBrocksDRYanezJAMultiple peaking phenomena in pharmacokinetic dispositionClin Pharmacokinet201049635137720481648
   PubMed Web of Science ®Google Scholar
• MurakamiTTakanoMIntestinal efflux transporters and drug absorptionExpert Opin Drug Metab Toxicol20084792393918624680
   PubMed Web of Science ®Google Scholar
• AgoramBWoltoszWSBolgerMBPredicting the impact of physiological and biochemical processes on oral drug bioavailabilityAdv Drug Deliv Rev200150Suppl 1S41S6711576695
   PubMed Web of Science ®Google Scholar
• WadaSKanoTMitaSThe role of inter-segmental differences in P-glycoprotein expression and activity along the rat small intestine in causing the double-peak phenomenon of substrate plasma concentrationDrug Metab Pharmacokinet20132829810322850759
   PubMed Web of Science ®Google Scholar
• MoulySPaineMFP-glycoprotein increases from proximal to distal regions of human small intestinePharm Res200320101595159914620513
   PubMed Web of Science ®Google Scholar
• MitschkeDReichelAFrickerGMoenningUCharacterization of cytochrome P450 protein expression along the entire length of the intestine of male and female ratsDrug Metab Dispos20083661039104518332081
   PubMed Web of Science ®Google Scholar